Prescription Drug Abuse: From Gabapentin to Buprenorphine and (Almost) Everything in Between
A case-based approach to the problem of prescription drug abuse, with a focus on medications not commonly addressed. Also, the latest evidence on tapering patients down and off of benzodiazepines
PRICE/PURCHASE -- $125
You must sign in or register register on this site before purchasing using the link on the upper right corner of this page. Only after registering will you see the "Add to Cart" button. To purchase, scroll to the bottom of the page and choose your purchase option (member/non-member) and click "Add to Cart."
PHYSICIANS: The California Society of Addiction Medicine (CSAM) is accredited by the Institute for Medical Quality/California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.
CSAM designates this live educational activity for a maximum of 3.5 AMA PRA Category 1 Credits™ Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 3.5 AMA/PRA Category 1 Credits™ for completing the Review Course.
Continuing education credit is also available for nurses, psychologists, pharmacists, physician assistants, therapists, and drug abuse counselors.
- Addiction medicine specialists who want an overview of the latest developments in the field and the relevance to clinical practice
- Primary care clinicians who want to get a better understanding of addiction and how to effectively manage patients with addictions in their practice
- Public health officials who want an understanding of the implications of the current state of addiction policy and treatment;
- Non-physicians who are involved in the treatment of patients with substance use disorders
- Anna Lembke, MD, Workshop Chair, Director, Stanford Addiction Medicine Program and Chief, Stanford Addiction Medicine Clinic, Stanford University School of Medicine
- Steven Batki, MD, Professor, Dept. of Psychiatry, UC San Francisco; Chief, Substance Abuse Programs, and Director, Addiction Research Program, VA Medical Center, San Francisco
- Judith Martin, MD, Medical Director of Substance Abuse Services, Dept. of Public Health, City & County of San Francisco
- David Kan, MD, Private Practice of Psychiatry and Forensic Psychiatry
- None of the faculty or planners of this activity reported any relevant financial relationships.
- 3.50 AMA Category 1
At the end of this activity learners should be able to
- develop a plan to taper patients off of benzodiazepines
- develop policies to prevend misuse of buprenorphine
- recognize signs of dependence in prescription medications other than opiates and benzodiazepines